Joan Kureczka

Partner at Bioscribe, Inc., but edging into new focus as a melodeon player at Borogroves. Music rules.

[Joan Kureczka @JKureczka]

Back into some communications work, given that music travel is off for now. Any media interested in some non-coronavirus science news, let me know! One interesting research paper on the horizon in autism diagnostics. And a stellar addiction panel for #BIOConvention.

[Joan Kureczka @JKureczka]

New preclinical research suggests the ability of BPN14770, an investigational drug under development by Tetra Therapeutics, to protect against memory loss and neuronal atrophy induced by amyloid beta1-42, a hallmark protein of Alzheimer’s disease. https://t.co/RjQO4cHJjw

[Joan Kureczka @JKureczka]

Tetra Discovery Partners Initiates Phase 2 Clinical Trial of BPN14770 in Patients with Early Alzheimer’s Disease. https://t.co/qxPXk9bCS4

[Joan Kureczka @JKureczka]

Hope you can join us for this discussion on Weds June 5! #BIO2019

[Joan Kureczka @JKureczka]

@LankumDublin OK -- how about the US west coast -- particularly San Francisco?

[Joan Kureczka @JKureczka]

Tetra Discovery Partners and Shionogi & Co., Ltd. collaborate on Alzheimer's drug candidate BPN14770 development and commercialization in Japan, Korea and Taiwan. https://t.co/ZcpaoC3wBe

[Joan Kureczka @JKureczka]

My last JPM. Ever. I hope. Said that last year, but in 2019 it's for real.

[BioWorld @BioWorld]

Little @CytoDyn looks for mighty push into cancer, immunology with @prostagene acquisition; BLA filing for PRO-140 in HIV still on tap for 1H 2019

[Joan Kureczka @JKureczka]

Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome, the most common genetic form of autism. https://t.co/wvjFFtdAPs

[Daniel S. Levine @dslevine]

Mark Gurney @TetraDiscovery discusses the companies experimental therapy for #fragileX and why it may benefit a range of neurodegenerative diseases on @GlobalGenes #RARECast https://t.co/IY7jI3jDB7

[Joan Kureczka @JKureczka]

@jessphoenix2018 @SecretaryZinke Yes indeed!

[Joan Kureczka @JKureczka]

Looking forward to this one -- it's going to be an interesting discussion. https://t.co/mHQKjvnFIW

[Joan Kureczka @JKureczka]

@BioWriterChik Just sent you an email. Hadn't heard from you previously, so hope some of these are of interest.

[Joan Kureczka @JKureczka]

Biomarkers in Alzheimer's was a focus at AAN, and will be at #BIO2018 too, from expert panel at Session 19826, June 6.

[Joan Kureczka @JKureczka]

@jeffSynthase Sorry -- not a member, so can't help.

[Joan Kureczka @JKureczka]

What do FDA policy changes re biomarkers in Alzheimer’s trials mean for drug and diagnostics developers? Hear from experts on Weds June 6, #BIO2018 Session 19826.

[Joan Kureczka @JKureczka]

What if you could monitor #oncology patients in real-time and adjust therapy as the disease changes or drug resistance develops? New cancer biomarkers, big data and analytics, and other advances can make this “Future of Cancer” a reality. Weds June 6, #BIO2018 Session 19824.

[Joan Kureczka @JKureczka]

Looking for hurdy-gurdy player in SF Bay Area, to collaborate. Alos French pipes. #hurdy-gurdy #balfolk #Borogroves

[Rob Wright @RobertFWright]

#CompaniesToWatch: #CytoDyn https://t.co/TRTRREzAN7 @WayneKoberstein